Sources Wilding JPH et al., "Once-Weekly Semaglutide in Adults with Overweight or Obesity," NEJM 2021 (STEP 1 trial, 14.9% weight loss at 68 weeks) Jastreboff AM et al., "Tirzepatide Once Weekly for the Treatment of Obesity," NEJM 2022 (SURMOUNT-1 trial, up to 22.5% weight loss at 72 weeks) FDA Warning Letter Database and April 15, 2026 Federal Register action on Category 2 peptide bulk substances, FDA.gov DOJ press releases, late 2025, on criminal guilty pleas in grey-market peptide distribution cases PubMed systematic reviews, 2024-2025, on BPC-157 preclinical and clinical evidence (multiple authors
A B12 deficiency in females can cause symptoms such as fatigue, tingling feet, or depression
And dysbiosis itself alters the balance of immune-promoting versus immune-regulating signals from the microbiome
How long does a reconstituted BPC-157 vial last